Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration

Mayo Clinic Proceedings

Volumn 83, Issue 2, 2008, Pages 231-234

  Diago, Teresa ^a   Pulido, Jose S ^a   Molina, Julian R ^a   Collet, Lucienne C ^a   Link, Thomas P ^a   Ryan Jr , Edwin H ^b  

^a MAYO CLINIC   (United States)

^b PA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SORAFENIB; VASCULOTROPIN;

AGED; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FLUORESCENCE ANGIOGRAPHY; HUMAN; LOW DRUG DOSE; MALE; MONOTHERAPY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT DURATION; VISUAL ACUITY;

EID: 39749180494     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.2.231     Document Type: Article

References (9)

1. RL Avery DJ Pieramici MD Rabena AA Castellarin MA Nasir MJ Giust Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 3 2006 363 372 e5. Epub 2006 Feb 3.
2. E Cabebe H Wakelee Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEFGR tyrosine kinase inhibitors Curr Treat Options Oncol 8 1 2007 15 27
3. MN Stein KT Flaherty Sorafenib and sutinib in renal cell carcinoma Clin Cancer Res 13 13 2007 3765 3770
4. D Strumberg H Richly RA Hilger Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 5 2005 Feb 10 965 972 Epub 2004 Dec 21.
5. D Strumberg JW Clark A Awada Safety, pharmacokinetics and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 4 2007 426 437
6. NM Bressler SB Bressler SL Fine Neovascular (exudative) age-related macular degeneration Stephen J. Ryan Retina 2006 Elsevier Mosby Philadelphia, PA 1075 1113
7. JZ Nowak Age-related macular degeneration (AMD): pathogenesis and therapy Pharmacol Rep 58 3 2006 353 363
8. QT Ho CJ Kuo Vascular endothelial growth factor: biology and therapeutic applications Int J Biochem Cell Biol 39 7–8 2007 1349 1357 Epub 2007 Apr 22.
9. Kernt M, Staehler M, Christian S, Kampik A, Neubauer AS. Resolution of macular oedema in occult choroidal neovascularization under oral sorafenib treatment [published online ahead of print October 1, 2007]. Acta Ophthalmol Scand. doi:10.1111/j.1600-0420.2007.01014.x.